The risk of lymph node metastases in 3951 surgically resected mucosal gastric cancers: implications for endoscopic resection

2016 ◽  
Vol 83 (5) ◽  
pp. 896-901 ◽  
Author(s):  
Kang Kook Choi ◽  
Jae Moon Bae ◽  
Su Mi Kim ◽  
Tae Sung Sohn ◽  
Jae Hyung Noh ◽  
...  
2012 ◽  
Vol 66 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Anna Maria Chiaravalli ◽  
Erika Longhi ◽  
Davide Vigetti ◽  
Francesca Isabella De Stefano ◽  
Sara Deleonibus ◽  
...  

AimImmunohistochemical and molecular studies have suggested an oncogenic role for JCV in gastrointestinal carcinomas, but at least in colorectal cancers, the data are far from being unambiguous.MethodsTwo large series of formalin-fixed paraffin-embedded gastric and colorectal cancers were analysed for the expression of JCV large T Antigen (T-Ag) with a panel of five antibodies, and for the presence of T-Ag DNA sequences using two PCR systems.ResultsIntense nuclear staining was observed in 54/116 (46%) colorectal, and in 92/234 (39%) gastric cancers, using the PAb416 monoclonal antibody against large T-Ag. In colorectal cancers, PAb416-positivity was directly related to the presence of chromosomal instability, lymph node metastases and a more advanced tumour stage, and inversely related to proximal tumour site and the presence of microsatellite instability (MSI). In gastric cancers, the glandular histotype, the presence of lymph node metastases, a low frequency of MSI and EBV infection, and a worse prognosis were significantly associated with PAb416 immunoreactivity. Moreover, at both these sites, PAb416 expression was significantly associated with p53 nuclear accumulation. No positivity was obtained with all the other four anti-T-Ag-antibodies, and molecular analysis failed to demonstrate the presence of JCV DNA sequences in tested cases.ConclusionsOur immunohistochemical and molecular results do not support the idea that JCV T-Ag has a role in gastrointestinal carcinogenesis. It is possible that PAb416, besides binding the viral protein, may cross-react with a hitherto undefined protein whose expression is associated with a distinct pathological profile and, at least in gastric cancers, with worse prognosis.


2012 ◽  
Author(s):  
Yasuyuki Shigematsu ◽  
Tohru Niwa ◽  
Satoshi Yamashita ◽  
Hirokazu Taniguchi ◽  
Ryoji Kushima ◽  
...  

2018 ◽  
Vol 88 (6) ◽  
pp. 912-918 ◽  
Author(s):  
Fernanda Cristina Simões Pessorrusso ◽  
Aloisio Felipe-Silva ◽  
Carlos Eduardo Jacob ◽  
Marcus Fernando Kodama Pertille Ramos ◽  
Venancio Avancini Alves Ferreira ◽  
...  

2019 ◽  
Vol 12 ◽  
pp. 175628481989255 ◽  
Author(s):  
Solène Dermine ◽  
Mahaut Leconte ◽  
Sarah Leblanc ◽  
Bertrand Dousset ◽  
Benoit Terris ◽  
...  

Background: Current guidelines recommend performing esophagectomy after endoscopic resection for early esophageal cancer when the risk of lymph node metastasis or residual cancer is found to be significant and endoscopic treatment is therefore noncurative. Our aim was to assess the safety and oncological outcomes of esophagogastric resection in this specific clinical setting. Patients and methods: A retrospective review from 2012 to 2018 was performed at four tertiary referral centers. All patients had a noncurative endoscopic resection of a clinical T1 esophageal cancer, followed by esophagectomy. Outcome measures were the rates of T0N0 specimens, overall survival, disease-free and cancer-specific survival, postoperative morbidity and mortality. Results: A total of 30 patients (13 with squamous cell carcinoma and 17 with adenocarcinoma) were included. The reasons for noncurative endoscopic resection were: positive vertical margins ( n = 12), squamous cell carcinoma with muscularis mucosae or submucosal layer invasion ( n = 3 and 9), adenocarcinoma with deep submucosal invasion ( n = 11), poorly differentiated tumor ( n = 6) and lymphovascular invasion ( n = 6). Overall, 63% of the esophagi were T0N0: most residual lesions were T1a metachronous lesions, and four (13%) patients had advanced pT status ( n = 3) or lymph node metastases ( n = 2). Overall survival, disease-free survival and cancer-specific survival were 83%, 75%, and 90% respectively. A total of 43% of patients had severe postoperative complications, and postoperative mortality was 7%. Conclusion: In this cohort, esophagectomy allowed the resection of residual advanced cancer or lymph node metastases in 13% of cases, at the cost of 43% severe morbidity and 7% mortality. Therefore, the possibility of close follow up needs to be balanced with a highly morbid surgical management in these patients.


2012 ◽  
Vol 4 (2) ◽  
pp. 268-274 ◽  
Author(s):  
YASUYUKI SHIGEMATSU ◽  
TOHRU NIWA ◽  
SATOSHI YAMASHITA ◽  
HIROKAZU TANIGUCHI ◽  
RYOJI KUSHIMA ◽  
...  

2018 ◽  
Vol 22 (2) ◽  
pp. 323-334 ◽  
Author(s):  
Han Hong Lee ◽  
Su Young Kim ◽  
Eun Sun Jung ◽  
Jinseon Yoo ◽  
Tae-Min Kim

Sign in / Sign up

Export Citation Format

Share Document